FDA Clearance Tracker · P930016-S012
VISX STAR EXCIMER LASER SYSTEM
Last checked: Nov 20, 2026Latest source record: Apr 27, 2001 (this decision)Source: openFDAMethods & limitations
Decided
Apr 27, 2001
Approved
Time to decision
287 days
Received Jul 14, 2000. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P930016-S012
- Device name
- VISX STAR EXCIMER LASER SYSTEM
- Applicant
- Amo Manufacturing USA, LLC
- Applicant location
- Milpitas, CA
- Received
- Jul 14, 2000
- Decided
- Apr 27, 2001
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Expedited review
- Yes, flagged as expedited in FDA's record.
- Original approval
- P930016
Device type
- Device type
- Excimer laser system (LZS)
- Device class
- Class III
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE VISX STAR S2 AND S3 EXCIMER LASER SYSTEMS. THE DEVICES ARE INDICATED FOR LASER IN-SITU KERATOMILEUSIS (LASIK) TREATMENTS: 1) IN PATIENTS WITH DOCUMENTED EVIDENCE OF A CHANGE IN MANIFEST REFRACTION OF NO MORE THAN 0.5 D (IN BOTH CYLINDER AND SPHERE COMPONENTS) FOR AT LEAST ONE YEAR PRIOR TO THE DATE OF PRE-OPERATIVE EXAMINATION; AND 2) IN PATIENTS 21 YEARS OF AGE OR OLDER IN TREATMENTS FOR THE REDUCTION OF ELIMINATION OF NATURALLY OCCURRING HYPEROPIA BETWEEN +05 AND +5.0 D SPHERE AT THE SPECTACLE PLANE WITH OR WITHOUT REFRACTIVE ASTIGMATISM UP TO +3.0 D, WITH A MAXIMUM MANIFEST REFRACTION SPHERICAL EQUIVALENT (MRSE) OF +6.0 D.
Source documents
Other decisions for Amo Manufacturing USA, LLC
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K223838 · Decided Apr 12, 2023 · 111 days after receipt
Device type: Ophthalmic Femtosecond Laser (OOE) · Ophthalmology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.